Ceftriaxone for the treatment of febrile episodes in nonneutropenic patients with hematooncological disease or HIV infection: Comparison of outpatient and inpatient care

Citation
G. Egerer et al., Ceftriaxone for the treatment of febrile episodes in nonneutropenic patients with hematooncological disease or HIV infection: Comparison of outpatient and inpatient care, CHEMOTHERA, 47(3), 2001, pp. 219-225
Citations number
20
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Pharmacology,"Pharmacology & Toxicology
Journal title
CHEMOTHERAPY
ISSN journal
0009-3157 → ACNP
Volume
47
Issue
3
Year of publication
2001
Pages
219 - 225
Database
ISI
SICI code
0009-3157(200105/06)47:3<219:CFTTOF>2.0.ZU;2-F
Abstract
Background: Patients with hematooncological disease or HIV infection and fe brile episodes are usually treated in hospital with broad-spectrum antibiot ics. The aim of this observational study was to assess the feasibility of a mbulatory parenteral antibiotic therapy in hematooncological or HIV-infecte d patients with confirmed or suspected infection. Methods: The results in a n outpatient treatment group were compared with those obtained in a group i nitially treated in hospital. Data were gathered on 90 outpatients and 72 i npatients. The inclusion criteria were fever greater than or equal to 37.5 degreesC with an identified focus of infection, fever greater than or equal to 38.0 degreesC of suspected bacterial origin with no identified focus of infection, leukocytosis greater than or equal to9,000/mul or C-reactive pr otein elevation greater than or equal to 10 mg/l. Results: Eighty outpatien ts and 69 inpatients were evaluable. Treatment in the outpatient group was begun with ceftriaxone. This led to defervescence in 87.5% of cases. The me an treatment duration was 7.1 days. Comparison of results in the outpatient s with those initially hospitalized for treatment showed similar success ra tes. The mean hospital stay in the latter group was 12.9 days. Conclusions: Ceftriaxone represents an effective treatment for outpatient management of febrile episodes in patients with hematooncological disease or HIV infecti on. Outpatient treatment is more cost-effective than inpatient care. Copyri ght (C) 2001 S. Karger AG, Basel.